+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nasal Polyps Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 112 Pages
  • January 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4896210
UP TO OFF until Mar 31st 2024

The Nasal Polyps Treatment Market is anticipated to witness a CAGR of nearly 6.2% during the forecast period. The major factors driving the growth of the market are the rising prevalence of various cancers, immunological disorders, and the increasing geriatric population.

For instance, the Centers for Disease Control and Prevention reports that in 2018, about 28.9 million adults in the United States were diagnosed with sinusitis which directly resulted in higher demand for the treatment fueling the growth of the market.

Furthermore, an increase in the R&D investment in pharmaceuticals with a strong pipeline of products is expected to boost the growth of the global market throughout the forecasted period.

Key Market Trends

Corticosteroids Segment by Drug Class is Expected to Hold the Largest Market Share in the Nasal Polyps Treatment Market

The corticosteroid segment is expected to account for the largest market share due to the increase in the demand for corticosteroids treatment and its availability in various dosage forms like injections, intranasal sprays, and drops according to the need of the patient. Also, the availability of various corticosteroids as topical formulations and aerosols which have the ability to decrease the size of nasal polyps, and thus heal the nasal polyps in patients has contributed to the significant share of revenue in the market. Furthermore, patient compliance for creams is more compared to other dosage forms available in the market.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall nasal polyps treatment market throughout the forecast period. This is mainly due to the increasing incidence of various cancers and allergic disorders such as asthma, sinusitis, and more, research activities in the United States coupled with increased approvals from regulatory bodies are likely to drive the growth of the nasal polyps treatment market.

The Asia Pacific is set to grow at the fastest rate during the forecast period, driven by the prevalence of allergic disorders and the steady growth of the pharmaceutical industry in recent years. China plays a pivotal role due in the Asia region to its high population and high extent of government initiatives to the healthcare sector. Ongoing trials in the region will further stimulate market growth in the region.

Competitive Landscape

The Nasal Polyps Treatment Market is moderately competitive and consists of several major players. Few of the major players are developing novel delivery systems to treat nasal polyps. which is expected to impel the global nasal polyps treatment market growth. For instance, in 2018, Intersect ENT Inc. launched SINUVA, a sinus implant containing mometasone furoate that is used to treat nasal polyps. Futhermore, few key players are entering into partnerships to develop and increase their market position globally. Some of the companies which are currently dominating the market are Sanofi S.A, OptiNose US, Merck & Co Inc, Intersect ENT Inc, and GlaxoSmithKline PLC

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Various Immunological Disorders along with the Increasing Geriatric Population
4.2.2 Huge Product Pipeline of Nasal Polyps Treatment with Growing Research Activities
4.3 Market Restraints
4.3.1 High Cost and Complications Associated with Sinus Surgeries
4.3.2 Adverse Reactions Associated with Steroid Therapies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Drug Class
5.1.1 Corticosteroids
5.1.2 Antibiotics
5.1.3 Leukotriene Inhibitors
5.1.4 Others
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Nasal
5.2.3 Others
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America United states Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Sanofi S.A
6.1.2 OptiNose US
6.1.3 Merck & Co Inc.
6.1.4 Intersect ENT Inc.
6.1.5 GlaxoSmithKline PLC
6.1.6 Teva Pharmaceutical Industries Ltd.
6.1.7 Regeneron Pharmaceuticals Inc.
6.1.8 F. Hoffmann-La Roche AG
6.1.9 Novartis International AG
6.1.10 Norton Waterford Ltd
6.1.11 Pfizer Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Sanofi S.A
  • OptiNose US
  • Merck & Co Inc.
  • Intersect ENT Inc.
  • GlaxoSmithKline PLC
  • Teva Pharmaceutical Industries Ltd.
  • Regeneron Pharmaceuticals Inc.
  • F. Hoffmann-La Roche AG
  • Novartis International AG
  • Norton Waterford Ltd
  • Pfizer Inc.